Login to Your Account



Peptech Acquiring EvoGenix In Cash, Stock Deal Worth A$156M

By Randall Osborne


Tuesday, May 8, 2007
With cash in its coffers from last year's sale of Domantis Ltd. to GlaxoSmithKline plc, Peptech Ltd. is buying out EvoGenix Ltd. for A$156 million (US$128.6 million), a 33 percent premium to the last trading price, in a bid to create yet another formidable antibody player. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription